WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
Revenue increased by 46.7% YoY to RMB 5,944 million Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 Adjusted net profit increased by 69.9% YoY to RMB 1,559 million,...
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits...
BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody –drug conjugate (ADC) to enter clinical development. BioDlink enabled IND...
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly...
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma The company enables seamless Europe–China tech transfer and faster biologics...
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. Demonstrating Robust Capabilities: Throughout the collaboration,...
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative...
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload...
The Hashemite Kingdom of Jordan Announces New Ocean Innovation Hub in Partnership with Innovative Blue Technology Company Voyacy Regen
Located in the Gulf of Aqaba, in the Hashemite Kingdom of Jordan, the Aqaba Marine Park will focus on building climate-resilient coastal marine infrastructure at an unprecedented scale NICE, France, June 10, 2025 /PRNewswire/ -- Today, His Majesty...
Samsung Biologics reports first quarter 2025 financial results
Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service...